Companies: 10,795·Total market cap: $144.5T

TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc.

RNAZNASDAQHealthcare● Active

$5.09

$-0.51(-9.11%)

Market Cap$4837032

P/E Ratio—

52W High$20.99

52W Low$3.82

Avg Volume46K

Open$5.54

Beta1.40

股票排行：Biotechnology·Healthcare·查看全部市值排行 →

TransCode Therapeutics, Inc.（RNAZ）股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · RNAZ · 截至 Jun 9, 2026

关键指标

EPS (TTM)$-48.65Earnings history

PE Ratio (TTM)—PE Ratio deep dive

Revenue (TTM)0.00Full revenue history

Dividend Yield不分红Dividend history

Shares Outstanding689,713Shares outstanding history

Next EarningsAug 18, 2026Est.Earnings history

探索 TransCode Therapeutics, Inc. 数据

分析师预测$— · Buy

股息不分红

盈利EPS $-52.59-11.56%

财务快照

FY 2025Revenue$0.00

202320242025

FY 2025Net Income-$34.7M▼ 106.87% YoY

202320242025

FY 2025EPS$-52.59▼ 11.56% YoY

202320242025

TTM:Revenue: $0.00Net Income: -$40.4MEPS: $-48.65View income statement →

分析师评级与目标价

Buy1 位分析师

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

12-Month Price Target

$—Low

$5.09Current

$—Avg Target

$—High

合计: 1 · 买入占比: 100.0%

竞争对手与同行

#TickerCompanyPriceChangeMkt Cap

TransCode Therapeutics, Inc.

$5.09-9.11%$4.8M #2

Acurx Pharmaceuticals, Inc.

$1.62-3.57%$2.6M #3

Aprea Therapeutics, Inc.

$0.73-0.96%$4.8M #4

Aptevo Therapeutics Inc.

$4.89+3.60%$6.1M #5

Bolt Biotherapeutics, Inc.

$4.72+3.51%$9.1M #6

$21.58-3.36%$34.5M

股票表现

1D-9.11%

1W+19.76%

1M-30.46%

3M-46.98%

YTD-25.48%

1Y-32.13%

5Y-100.00%

关于 TransCode Therapeutics, Inc.

CEOPhilippe Calais

IPO DateJul 8, 2021

Employees7

CountryUS

Websitetranscodetherapeutics.com

TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease.…

Biotechnology HealthcareNASDAQUS

关于股票概览与关键数据

TransCode Therapeutics, Inc.（RNAZ）是 Biotechnology 行业的 Healthcare 类公司，于 Jul 8, 2021 在 NASDAQ 上市。截至最近交易日，RNAZ 股价为 $5.09，市值约为 $4.8M。过去12个月累计回报 -32.13%，年初至今回报 -25.48%。

根据 1 位华尔街分析师，TransCode Therapeutics, Inc. 股票共识评级为Buy，12个月平均目标价为 $—。2025 财年 TransCode Therapeutics, Inc. 营收 —，净利润 -$34.7M。更多数据（营收历史、盈利、股息、市盈率）请使用上方标签页。

常见问题

截至最近一个交易日，TransCode Therapeutics, Inc.（RNAZ）股价为 $5.09，在 NASDAQ 上市，52周区间为 $3.82 – $20.99。

RNAZ 最新股价RNAZ quote todaylive ticker 实时行情

数据来源：Financial Modeling Prep最后更新：Jun 9, 2026本内容不构成投资建议